Journal of diabetes and its complications最新文献

{"title":"Low imaging-detected muscle mass as a prognostic factor for overall and amputation-free survival in patients undergoing lower extremity amputation","authors":"Elli Kykkänen ,&nbsp;Ilkka Kaartinen ,&nbsp;Otso Arponen ,&nbsp;Miska Vuorlaakso","doi":"10.1016/j.jdiacomp.2025.109119","DOIUrl":"10.1016/j.jdiacomp.2025.109119","url":null,"abstract":"<div><h3>Background</h3><div>Amputations and sarcopenia are both increasing globally. This study investigates the association between imaging-detected muscle mass and outcomes after lower extremity amputation.</div></div><div><h3>Methods</h3><div>The sample population included patients undergoing amputation with abdominal computed tomography (CT) scans. The psoas muscle index (PMI) and skeletal muscle index (SMI) were evaluated at the level of the 3rd lumbar vertebra. Overall survival (OS) and amputation-free survival (AFS) were evaluated.</div></div><div><h3>Results</h3><div>A total of 72 patients (mean age: 66.4 ± 18.5 years) were evaluated in the study. Lower PMI and SMI were associated with decreased OS (PMI/SMI: HR 4.120, 95 % confidence interval [CI]: 1.692–10.032/HR 2.487, 95 % CI: 1.091–5.666) and AFS after the first amputation (PMI/SMI: HR 3.561, 95 % CI: 0.938–13.516/HR 3.982, 95 % CI: 1.080–14.677) in univariate models. Low PMI and SMI remained significant in multivariable models adjusted for age, sex, and amputation level.</div></div><div><h3>Conclusions</h3><div>Imaging-detected low muscle mass is associated with impaired OS and AFS in patients undergoing lower extremity amputation. Evaluation of muscle mass from available CT scans may provide useful information for clinical decision-making.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109119"},"PeriodicalIF":2.9,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144536218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor regarding “High rate of complications in a real-world cohort of youth with T2D: a multicenter analysis”","authors":"Rachana Mehta ,&nbsp;Ranjana Sah","doi":"10.1016/j.jdiacomp.2025.109117","DOIUrl":"10.1016/j.jdiacomp.2025.109117","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109117"},"PeriodicalIF":2.9,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144536219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneity of treatment effects of glucose-lowering drug classes for type 2 diabetes: LEGEND-T2DM network real-world evidence","authors":"David M. Dávila-García ,&nbsp;Thomas Falconer ,&nbsp;Nicole Pratt ,&nbsp;Karthik Natarajan ,&nbsp;George Hripcsak","doi":"10.1016/j.jdiacomp.2025.109114","DOIUrl":"10.1016/j.jdiacomp.2025.109114","url":null,"abstract":"<div><h3>Aims</h3><div>To assess heterogeneity of treatment effects (HTE) of glucose-lowering drug classes by clinical (cardiovascular [CV] risk, renal impairment) and demographic (age, sex) subgroups in adults with type 2 diabetes mellitus (T2D).</div></div><div><h3>Methods</h3><div>The LEGEND-T2DM network identified 4,746,939 adults with T2D on metformin monotherapy who initiated one of four glucose-lowering drug classes: glucagon-like peptide-1 receptor agonists (GLP-1 RA), sodium-glucose cotransporter 2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitor (DPP-4i) or sulfonylureas. HTE was assessed between glucose-lowering drug classes by clinical (low CV risk vs. higher CV risk; without renal impairment vs. renal impairment) and demographic (lower vs. middle vs. older age; male vs. female) subgroups. Outcomes included MACE (primary), acute myocardial infarction, stroke, sudden cardiac death and safety endpoints.</div></div><div><h3>Results</h3><div>Pairwise differences (<em>n</em> = 1115 tests) between adjusted hazard ratios (HRs) showed 49 nominally significant associations (<em>p</em> &lt; 0.05) and one statistically significant difference after Bonferroni correction (<em>p</em> &lt; 4.5 × 10⁻⁵). Among older subjects (vs. younger), those taking GLP-1 RA (vs. sulfonylureas) had statistically significant difference in risk of hypoglycemia (HRs: lower age, 0.53 ± 0.14 vs. older age, 0.20 ± 0.05, <em>p</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>HTE among glucose-lowering drug classes by clinical and demographic subgroups may provide guidance to generate hypothesis-testing studies to inform T2D treatment decisions.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 9","pages":"Article 109114"},"PeriodicalIF":2.9,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144502148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DNA repair and inflammatory response genes play a central role in protecting patients with long-standing type 1 diabetes from vascular complications","authors":"Türküler Özgümüş ,&nbsp;Oksana Sulaieva ,&nbsp;Most Champa Begum ,&nbsp;Ola Ekström ,&nbsp;Ruchi Jain ,&nbsp;Peter Nilsson ,&nbsp;Kari Anne Sveen ,&nbsp;Tore Julsrud Berg ,&nbsp;Valeriya Lyssenko","doi":"10.1016/j.jdiacomp.2025.109112","DOIUrl":"10.1016/j.jdiacomp.2025.109112","url":null,"abstract":"<div><h3>Aims</h3><div>Individuals with type 1 diabetes (T1D) are typically diagnosed at a young age and exposed to lifelong hyperglycaemia. Despite improved metabolic control, the risk of vascular complications remains challenging. However, some individuals remain free from developing major diabetic complications even after long duration, so-called “escapers”. This study investigated transcriptomic biomarkers linked to protection from microvascular complications in the Dialong cohort of long-standing T1D.</div></div><div><h3>Methods</h3><div>Differential gene expression analysis was conducted to identify differences between patients with long-term T1D without complications (non-progressors), those with vascular complications (progressors), and healthy controls without T1D.</div></div><div><h3>Results</h3><div>Among the differentially expressed genes, <em>HERC2</em>, <em>S1PR3</em>, <em>RNASE3</em>, and <em>CD33</em> were significantly altered between non-progressors and progressors. Functional annotation analyses identified the strongest mechanisms across all groups to be linked to post-translational protein modification, such as Lys-Gly isopeptide bond involved in SUMOylation (p = 5e-17) - a biological process of covalent attachment and detachment of SUMO (Small Ubiquitin-like Modifier) small proteins to modify protein function. The second-ranked pathway was enrichment of DNA repair/damage (p = 6e-5), cell cycle and division (p = 4e-4), and immune response genes (p = 1e-7).</div></div><div><h3>Conclusions</h3><div>These findings underscore the role of post-translational protein modifications, DNA repair pathways and immune tolerance in protecting long-standing T1D patients from vascular complications.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 9","pages":"Article 109112"},"PeriodicalIF":2.9,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144470793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A mediation analysis assessing if interleukin-6 mediates the association between obesity and new-onset type-2-diabetes","authors":"Nicholas W. Carris ,&nbsp;Rahul Mhaskar ,&nbsp;Emily Coughlin ,&nbsp;Easton Bracey ,&nbsp;Hariom Yadav ,&nbsp;Ganesh V. Halade ,&nbsp;Matthew J. Valente","doi":"10.1016/j.jdiacomp.2025.109110","DOIUrl":"10.1016/j.jdiacomp.2025.109110","url":null,"abstract":"<div><div>Obesity and chronic low-level inflammation increase chronic disease development. The study objective was to better understand how obesity is linked to inflammation and inflammation to new-onset type-2-diabetes. This observational mediation analysis found that 8.1 % of the total effect of increasing BMI on new-onset type-2-diabetes risk was mediated by interleukin-6.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 9","pages":"Article 109110"},"PeriodicalIF":2.9,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144502149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modulation of the sodium-chloride cotransporter by insulin in auditory cells: A potential link to diabetes-related hearing complications","authors":"Ann-Ki Pålbrink ,&nbsp;Måns Magnusson ,&nbsp;Eva Degerman","doi":"10.1016/j.jdiacomp.2025.109111","DOIUrl":"10.1016/j.jdiacomp.2025.109111","url":null,"abstract":"<div><h3>Aim</h3><div>While diabetes mellitus (types 1 and 2) is known to negatively impact vestibular and auditory function, the precise mechanisms underlying this effect are not fully understood. Building on our previous findings, which demonstrated the presence of insulin signaling components within the human saccule and identified the sodium transporter ENaC as a target for insulin signaling in HEI-OC1 auditory cells, this study aimed to investigate the role of the sodium-chloride cotransporter (NCC) in insulin signaling and to identify the upstream signaling pathways involved.</div></div><div><h3>Methods</h3><div>We utilized a combination of kinase inhibitors, ceramide treatments, and western blot analysis to evaluate the effects of insulin and induced insulin resistance on NCC phosphorylation and the related upstream signaling pathways in HEI-OC1 cells.</div></div><div><h3>Results</h3><div>Insulin treatment resulted in a dose-dependent increase in NCC phosphorylation. This phosphorylation was significantly attenuated by the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin, the protein kinase B (PKB) inhibitor MK2206, the protein kinase A (PKA) inhibitor H89, and ceramide. Conversely, the serum/glucocorticoid regulated kinase 1 (SGK1) inhibitor GSK650394 did not affect insulin-induced NCC phosphorylation, although it did block insulin-induced phosphorylation of the SGK1 substrate, NDRG1. Furthermore, WNK1 (With-No-Lysine Kinase 1), a proposed downstream target of PKB and a regulator of NCC, also exhibited insulin-induced phosphorylation, dependent on PI3K, PKB, PKA, and ceramide.</div></div><div><h3>Conclusions</h3><div>These findings indicate that insulin promotes NCC phosphorylation, likely through the PI3K/PKB/WNK1 signaling pathway, with a possible contribution from cAMP/PKA signaling. This suggests that insulin-mediated NCC phosphorylation may influence inner ear sodium homeostasis. This mechanism could potentially contribute to the inner ear dysfunction observed in diabetes.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 9","pages":"Article 109111"},"PeriodicalIF":2.9,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144470792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes of patients with Polyvascular disease admitted with an acute diabetic foot ulcer","authors":"Nitzan Tal ,&nbsp;Isca Hershkowitz ,&nbsp;Kobi Gorin ,&nbsp;Michal Leibovitch ,&nbsp;Shahar Peled ,&nbsp;Karen Olshtain-Pops ,&nbsp;Jonathan Lorber ,&nbsp;Tamar Fisher-Negev ,&nbsp;Anat Tsur ,&nbsp;Amir Haze ,&nbsp;Yechiel N. Gellman ,&nbsp;Avivit Cahn","doi":"10.1016/j.jdiacomp.2025.109109","DOIUrl":"10.1016/j.jdiacomp.2025.109109","url":null,"abstract":"<div><h3>Aims</h3><div>Diabetic foot ulcer (DFU) is a common cause of admission in patients with diabetes. Diabetes increases the likelihood of inpatient Major Adverse Cardiovascular Events (MACE), and the presence of polyvascular disease (PD), defined by the presence of atherosclerosis in two or more arterial beds, further amplifies this risk. We assessed the impact of PD on outcomes in patients admitted due to a DFU.</div></div><div><h3>Methods</h3><div>In this retrospective single-center study, we enrolled adult patients admitted to the diabetic foot unit between 2014 and 2019. The primary outcome was a composite of inpatient MACE or death. Secondary outcomes included amputations, leg revascularization, duration of admission and 1-year mortality. We additionally collected survival data till the end of 2023.</div></div><div><h3>Results</h3><div>A total of 537 patients were enrolled in the study, 264 suffering of PD. The primary endpoint occurred in 12.5 % and 4.4 % of patients with vs. without PD (<em>p</em> = 0.001). Patients with PD had an increased incidence of vascular interventions (42 % vs. 19.4 %, <em>p</em> &lt; 0.001), any amputation (67.4 % vs. 48.4 %, <em>p</em> &lt; 0.001) and major amputation (35.6 % vs. 13.2 %, p &lt; 0.001). They had longer admissions (median 19 vs. 17 days, <em>p</em> = 0.002) and higher 1-year mortality rates (33.0 % vs. 12.1 %, <em>p</em> &lt; 0.001). During 10-year follow up (median 3.3 years) median survival was 2.0 vs. 5.9 years for patients with vs. without PD (p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>PD in patients admitted with a DFU is associated with poor inpatient and long-term outcomes. This highlights the need for comprehensive risk assessment, optimization of in-patient management and long-term control of cardiovascular risk factors.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 9","pages":"Article 109109"},"PeriodicalIF":2.9,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Technosphere insulin in the treatment of Type 1 diabetes mellitus: A systematic review and meta-analysis","authors":"Vitória Karoline Justino Dos Santos ,&nbsp;Marcelo Lucas De Lima Prado ,&nbsp;Gabriela Simões Noel Da Silva ,&nbsp;Iapunira Catarina Sant'anna Aragão ,&nbsp;Felipe Matheus Sant'anna Aragão ,&nbsp;Vitor Henrique Justino Dos Santos ,&nbsp;Larissa Calixto Hespanhol ,&nbsp;Vanessa Lins De Menezes ,&nbsp;Francisco Prado Reis ,&nbsp;José Aderval Aragão","doi":"10.1016/j.jdiacomp.2025.109108","DOIUrl":"10.1016/j.jdiacomp.2025.109108","url":null,"abstract":"<div><h3>Aims</h3><div>Conduct a systematic review and meta-analysis comparing Technosphere Insulin and traditional ultra-rapid insulin in T1DM.</div></div><div><h3>Methods</h3><div>Researchers conducted a systematic search on databases to identify randomized controlled trials (RCTs) comparing two insulin regimens—TI and RAI —in patients with type 1 diabetes mellitus (T1DM). The outcomes of interest included changes in HbA1c levels, body weight, and rates of overall and severe hypoglycemia.</div></div><div><h3>Results</h3><div>Four RCTs were included. There was no significant difference between groups on change in HbA1c (MD 0.04; 95 % CI −0.19–0.27; <em>p</em> = 0.74; I² = 0 %). In terms of body weight change, the TI group exhibited significantly less (MD −1.05; 95 % CI −1.63 to −0.46; <em>p</em> = 0.0005; I² = 0 %) compared to the RAI group. Adverse events such as overall hypoglycemia (RR −0.97; 95 % CI 0.94–1.01; <em>p</em> = 0.24; I² = 26 %) and severe hypoglycemia (RR 0.63; 95 % CI 0.46–0.87; <em>p</em> = 0.005; I² = 0 %), were significantly more frequent in the RAI group.</div></div><div><h3>Conclusions</h3><div>The use of Technosphere Insulin (TI) in T1DM patients did not show a difference in HbA1c, suggesting that TI may offer advantages in weight stability and a lower incidence of hypoglycemic events compared to rapid-acting insulin (RAI).</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 9","pages":"Article 109108"},"PeriodicalIF":2.9,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144253490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NerveCheck master to screen patients with type 1 or type 2 diabetes for peripheral and cardiac autonomic neuropathy","authors":"Raffaele Galiero ,&nbsp;Amel Rezki ,&nbsp;Vittorio Simeon ,&nbsp;Domenico Beccia ,&nbsp;Maria Alfano ,&nbsp;Alfredo Caturano ,&nbsp;Ferdinando Carlo Sasso ,&nbsp;Paul Valensi","doi":"10.1016/j.jdiacomp.2025.109107","DOIUrl":"10.1016/j.jdiacomp.2025.109107","url":null,"abstract":"<div><h3>Aim</h3><div>NerveCheck Master (NCKM) is a portable device designed to assess vibration, warm, cold and heat pain perception thresholds. NCKM was shown to offer good diagnostic accuracy for diabetic peripheral neuropathy (DPN). Cardiac autonomic neuropathy (CAN) remains underdiagnosed. We assessed the role of NCKM against Michigan Neuropathy Screening Instrument (MNSI) to screen patients with diabetes for both DPN and CAN.</div></div><div><h3>Methods</h3><div>DPN was assessed using the 4 NCKM tests and MNSI, and CAN using standard tests, in 76 patients with type 1 (T1DM) and 65 with type 2 diabetes mellitus (T2DM).</div></div><div><h3>Results</h3><div>Among patients with T1DM and T2DM, DPN prevalence was 26.3 % and 35.4 %, respectively, according to MNSI score (≥2.5), and 61.8 % and 70.8 % according to NCKM (≥2 abnormal tests), and CAN prevalence was 22.4 % and 41.4 %, respectively. Among patients with T1DM, CAN prevalence was markedly higher in those with DPN according to NCKM than in those without (31.9 % <em>vs</em> 6.9 %, <em>p</em> = 0.011), with a far lesser difference among patients with T2DM. The cut-off of two abnormal tests offers good sensitivity and negative predictive value for the detection of patients with CAN, particularly among patients with T1DM (88.2 % and 93.1 %, respectively).</div></div><div><h3>Conclusion</h3><div>NCKM detects more patients with DPN and its positivity is associated with a higher likelihood of CAN. Using NCKM appears an attractive approach to identify patients to screen for CAN and to improve the yield of CAN tests.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 9","pages":"Article 109107"},"PeriodicalIF":2.9,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of gestational and type 2 diabetes on fetal endothelial cell miRNA expression","authors":"Samar Sultan ,&nbsp;Reham Sabeeh","doi":"10.1016/j.jdiacomp.2025.109106","DOIUrl":"10.1016/j.jdiacomp.2025.109106","url":null,"abstract":"<div><h3>Aims</h3><div>Fetal exposure to hyperglycemia <em>in utero</em> have been suggested to induce epigenetic changes through expression of various miRNAs, and cause dysfunctional endothelium connected with elevated risk of cardiovascular disease (CVD) in offspring during early adulthood. In this study, we investigated whether hyperglycemia-induced changes in the expression of 28 fetal endothelial microRNAs (miRNAs) are associated with endothelial dysfunction and CVD.</div></div><div><h3>Methods</h3><div>Differentially expressed miRNAs in TaqMan miRNA human arrays were quantified using qPCR.</div></div><div><h3>Results</h3><div>The expression of miR-140-3p, miR-1307-5p, miR-342-3p, and miR-16-5p was significantly reduced in human umbilical vein endothelial cells (HUVECs) from females with gestational diabetes (GDM-UVECs) compared with that of the control group. Meanwhile, in type 2 diabetes (T2D-HUVECs), miR-126-3p and miR-27a-5p were significantly reduced, while miR-27b-3p was significantly increased. Furthermore, miR-29b-3p expression was upregulated in both GDM– and T2D-HUVECs compared with that in the control. The expression of fibroblast growth factor 11 (<em>FGF11</em>) mRNA—a target of dysregulated miR-342-3p—was downregulated in GDMHUVECs compared with that in the control.</div></div><div><h3>Conclusions</h3><div>Altered miRNA and target <em>FGF11</em> mRNA expression may contribute mechanistically to endothelial dysfunction in diabetic HUVECs when maintained under normal glucose conditions for several passages.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 9","pages":"Article 109106"},"PeriodicalIF":2.9,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}